Clinical trials and biomarker development with molecularly targeted agents and radiotherapy

被引：0
|
作者：
Neesha Dhani
Lillian L. Siu
机构：
[1] University of Toronto,Princess Margaret Hospital, Division of Medical Oncology and Hematology, Department of Medicine
[2] Division of Medical Oncology and Hematology,Princess Margaret Hospital
来源：
Cancer and Metastasis Reviews | 2008年 / 27卷
关键词：
Clinical trials; Biomarker; Radiotherapy; Genomics; Prognosis; Pharmacokinetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：339 / 349
页数：10
相关论文
共 50 条
  • [21] Biomarker Tests for Molecularly Targeted Therapies: Laying the Foundation and Fulfilling the Dream
    Lyman, Gary H.
    Moses, Harold L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (17) : 2061 - +
  • [22] Targeted therapies for gallbladder cancer: an overview of agents in preclinical and clinical development
    De Lorenzo, Stefania
    Garajova, Ingrid
    Stefanini, Bernardo
    Tovoli, Francesco
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2021, 30 (07) : 759 - 772
  • [23] Pragmatic dose-escalation methods incorporating relative dose intensity assessment for molecularly targeted agents in phase I trials
    Hirakawa, Akihiro
    Tanaka, Yuichi
    Kaneko, Shuhei
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2019, 16
  • [24] An adaptive dose-finding method using a change-point model for molecularly targeted agents in phase I trials
    Sato, Hiroyuki
    Hirakawa, Akihiro
    Hamada, Chikuma
    STATISTICS IN MEDICINE, 2016, 35 (23) : 4093 - 4109
  • [25] A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults' trials
    Paoletti, Xavier
    Geoerger, Birgit
    Doz, Francois
    Baruchel, Andre
    Lokiec, Francois
    Le Tourneau, Christophe
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (10) : 2392 - 2402
  • [26] The pipeline of targeted therapies under clinical development for primary Sjogren's syndrome: A systematic review of trials
    Felten, Renaud
    Scher, Florence
    Sibilia, Jean
    Gottenberg, Jacques-Eric
    Arnaud, Laurent
    AUTOIMMUNITY REVIEWS, 2019, 18 (06) : 576 - 582
  • [27] Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials
    Kim, Seung Tae
    Kim, Kyoung-Mee
    Kim, Nayoung K. D.
    Park, Joon Oh
    Ahn, Soomin
    Yun, Jae-Won
    Kim, Kyu-Tae
    Park, Se Hoon
    Park, Peter J.
    Kim, Hee Cheol
    Sohn, Tae Sung
    Choi, Dong Il
    Cho, Jong Ho
    Heo, Jin Seok
    Kwon, Wooil
    Lee, Hyuk
    Min, Byung-Hoon
    Hong, Sung No
    Park, Young Suk
    Lim, Ho Yeong
    Kang, Won Ki
    Park, Woong-Yang
    Lee, Jeeyun
    ONCOLOGIST, 2017, 22 (10) : 1169 - 1177
  • [28] Clinical Trials that Utilize MRS as a Biomarker
    Lin, Alexander
    Rowland, Ben
    Griffiths, John R.
    EMAGRES, 2016, 5 (02): : 1139 - 1145
  • [29] A hierarchical Bayes model for biomarker subset effects in clinical trials
    Chen, Bingshu E.
    Jiang, Wenyu
    Tu, Dongsheng
    COMPUTATIONAL STATISTICS & DATA ANALYSIS, 2014, 71 : 324 - 334
  • [30] OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis
    Kraus, V. B.
    Blanco, F. J.
    Englund, M.
    Henrotin, Y.
    Lohmander, L. S.
    Losina, E.
    Onnerfjord, P.
    Persiani, S.
    OSTEOARTHRITIS AND CARTILAGE, 2015, 23 (05) : 686 - 697
12345